OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
3390$0.2756

Tycoon Group Holdings Ltd

PharmaceuticalsVerified

Tycoon Group Holdings Ltd has a market capitalization of $241.38 million and a price-to-earnings ratio of 15.4, indicating a moderate valuation relative to earnings. The company's price-to-book ratio of 0.45 suggests that the market values the company at a discount to its book value. The enterprise value to EBITDA ratio of 13.76 and enterprise value to revenue ratio of 0.55 indicate that the company is valued at a relatively low multiple of its earnings and revenue. The company's profitability metrics show a return on equity of 2.92% and a return on assets of 1.34%, both of which are below the industry median for pharmaceuticals. The gross profit margin of 24.7% and operating margin of 4.0% suggest that the company is generating modest profitability, with a significant portion of revenue consumed by operating expenses. Tycoon Group Holdings Ltd's revenue is distributed across three segments: Distribution, Retail Stores, and Online Stores. The company's geographic exposure is not explicitly detailed in the input data, but the presence of online stores suggests a potential for broader geographic reach. The company's revenue concentration across segments is not disclosed, but the presence of three distinct segments indicates a diversified revenue model. The company's growth trajectory is not explicitly detailed in the input data, but the current liquidity position and capital structure suggest a stable but not rapidly growing business. The company's free cash flow of $39.57 million and operating cash flow of $96.95 million indicate a positive cash flow position, which supports the company's liquidity and operational flexibility. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company's cash reserves are insufficient to cover its long-term debt obligations. The debt-to-equity ratio of 0.8 indicates a moderate level of leverage, which is below the industry median for pharmaceuticals. Recent events and filings for Tycoon Group Holdings Ltd are not explicitly detailed in the input data. However, the company's financial snapshot and valuation metrics suggest a stable but not rapidly growing business with a moderate level of leverage and a positive cash flow position.

30-day price · 3390-0.01 (-3.5%)
Low$0.23High$0.30Close$0.28As of21 May, 00:00 UTC
Profile
CompanyTycoon Group Holdings Ltd
Ticker3390.HK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Tycoon Group Holdings Ltd is an investment holding company engaged in the provision of proprietary Chinese medicine (PCM) and health supplement products, operating through distribution, retail stores, and online stores segments.

Classification. Tycoon Group Holdings Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Tycoon Group Holdings Ltd has a market capitalization of $241.38 million and a price-to-earnings ratio of 15.4, indicating a moderate valuation relative to earnings. The company's price-to-book ratio of 0.45 suggests that the market values the company at a discount to its book value. The enterprise value to EBITDA ratio of 13.76 and enterprise value to revenue ratio of 0.55 indicate that the company is valued at a relatively low multiple of its earnings and revenue. The company's profitability metrics show a return on equity of 2.92% and a return on assets of 1.34%, both of which are below the industry median for pharmaceuticals. The gross profit margin of 24.7% and operating margin of 4.0% suggest that the company is generating modest profitability, with a significant portion of revenue consumed by operating expenses. Tycoon Group Holdings Ltd's revenue is distributed across three segments: Distribution, Retail Stores, and Online Stores. The company's geographic exposure is not explicitly detailed in the input data, but the presence of online stores suggests a potential for broader geographic reach. The company's revenue concentration across segments is not disclosed, but the presence of three distinct segments indicates a diversified revenue model. The company's growth trajectory is not explicitly detailed in the input data, but the current liquidity position and capital structure suggest a stable but not rapidly growing business. The company's free cash flow of $39.57 million and operating cash flow of $96.95 million indicate a positive cash flow position, which supports the company's liquidity and operational flexibility. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company's cash reserves are insufficient to cover its long-term debt obligations. The debt-to-equity ratio of 0.8 indicates a moderate level of leverage, which is below the industry median for pharmaceuticals. Recent events and filings for Tycoon Group Holdings Ltd are not explicitly detailed in the input data. However, the company's financial snapshot and valuation metrics suggest a stable but not rapidly growing business with a moderate level of leverage and a positive cash flow position.
Key takeaways
  • Tycoon Group Holdings Ltd has a moderate valuation with a price-to-earnings ratio of 15.4 and a price-to-book ratio of 0.45.
  • The company's profitability metrics, including a return on equity of 2.92% and a return on assets of 1.34%, are below the industry median for pharmaceuticals.
  • The company's revenue is distributed across three segments: Distribution, Retail Stores, and Online Stores, indicating a diversified revenue model.
  • The company's free cash flow of $39.57 million and operating cash flow of $96.95 million support its liquidity and operational flexibility.
  • The company's risk assessment indicates a medium liquidity risk and a low dilution risk, with a debt-to-equity ratio of 0.8.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$1.10B
Gross profit$270.0M
Operating income$43.5M
Net income$15.7M
R&D
SG&A
D&A
SBC
Operating cash flow$97.0M
CapEx-$485.0k
Free cash flow$39.6M
Total assets$1.17B
Total liabilities$633.3M
Total equity$537.0M
Cash & equivalents$70.3M
Long-term debt$428.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$0.27
Market cap$241.4M
Enterprise value$599.1M
P/E15.4
Reported non-GAAP P/E
EV/Revenue0.6
EV/Op income13.8
EV/OCF6.2
P/B0.5
P/Tangible book0.5
Tangible book$537.0M
Net cash-$357.7M
Current ratio1.4
Debt/Equity0.8
ROA1.3%
ROE2.9%
Cash conversion6.2%
CapEx/Revenue-0.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric3390Activity
Op margin4.0%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin1.4%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin24.6%47.8% medp25 27.6% · p75 68.9%bottom quartile
CapEx / revenue-0.0%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity80.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 10:34 UTC#d2edda0a
Market quoteclose HKD 0.27 · shares 0.89B diluted
no public URL
2026-05-03 15:25 UTC#197a80d3
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 15:27 UTCJob: bec2eb28